X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.
Lead Product(s): LBP-EC01
Therapeutic Area: Infections and Infectious Diseases Product Name: LBP-EC01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $23.9 million Upfront Cash: Undisclosed
Deal Type: Funding January 23, 2024
Details:
LBP-EC01 is a Locus crPhage® therapy in development for the treatment of urinary tract infections and other infections caused by the pathogen Escherichia coli (E. coli). It is a bacteriophage cocktail engineered with a CRISPR-Cas3 construct targeting the E. coli genome.
Lead Product(s): LBP-EC01,Trimethoprim,Sulfamethoxazole
Therapeutic Area: Infections and Infectious Diseases Product Name: LBP-EC01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Proceeds from this financing will support the advancement of lead candidate LBP-EC01, a crPhage precision medicine targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs).
Lead Product(s): LBP-EC01
Therapeutic Area: Infections and Infectious Diseases Product Name: LBP-EC01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Artis Ventures
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 18, 2022
Details:
Locus is developing two biotherapeutics to address unmet medical needs: precision products to fight deadly infections, including those caused by multi-drug resistant bacteria; and engineered bacteriophage therapies that utilize bacteria resident in the body.
Lead Product(s): Engineered Bacteriophage
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 19, 2021
Details:
LBP-EC01 is a CRISPR-Cas3-enhanced bacteriophage precision medicine product targeting E. coli bacteria causing urinary tract infections. Phase 1b trial shows safety and tolerability for LBP-EC01 and help support the overall safety profile for Locus' phage therapy platform.
Lead Product(s): LBP-EC01
Therapeutic Area: Infections and Infectious Diseases Product Name: LBP-EC01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
Funding will support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01.
Lead Product(s): LBP-EC01
Therapeutic Area: Infections and Infectious Diseases Product Name: LBP-EC01
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $144.0 million Upfront Cash: $77.0 million
Deal Type: Funding September 30, 2020
Details:
It is the world's first controlled clinical trial for a recombinant bacteriophage therapy this trial represents a significant milestone for the field.
Lead Product(s): LBP-EC01
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
